CClinicalTrials.gg
WithdrawnNCT01127334Updated Apr 4, 2012

Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device

An observational study in Systolic Heart Failure, sponsored by University of Mississippi Medical Center. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-04.

Sponsored by University of Mississippi Medical Center · Observational

Why this study was withdrawn
Principal Investigator terminated study
Study type
Observational
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Out of all the patients that receive a CRT-D ( a dual chamber pacemaker with defibrillator ) for cardiac resynchronization therapy there is approximately one-third that do not respond. We believe that by using a simple technique that includes routine echocardiography that are normally performed in these patients could help us better understand how to program their device to reach better optimization.

02

Conditions studied

  • Systolic Heart Failure

Keywords

  • Dyssynchrony
  • Cardiac resynchronization therapy
03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

Browse Heart Failure studies →

Lead sponsor

University of Mississippi Medical Center is the lead sponsor of 125 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cardiology and electrophysiology clinics

Inclusion criteria

  1. Adults age 18-110 years
  2. Must have a CRT-D (A biventricular pacemaker with defibrillator)
  3. Last optimization of their device (CRT-D) must not have been done in the past 3 months
  4. Must be optimal heart failure medical regimen. This includes target dose of beta-blocker and angiotensin converting enzyme inhibitor (ACE-I) (or equivalent; i.e angiotensin receptor blocker (ARB); or balanced preload and afterload reducers with hydralazine and nitrates.)

Exclusion criteria

Exclusion Criteria:

  1. Less than 18 years of age or greater than 110 years old.
  2. Does not have a CRT-D
  3. Optimization of their device has occurred in the past 3 months
  4. Not on optimal medical therapy for heart failure as listed in the inclusion criteria.
05

Study design

Time perspective
Prospective
Enrollment
0 participants (actual)

Groups and cohorts

  • Systolic Heart Failure, Dyssynchrony, CRT-D

    Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.

06

Study locations

1 site
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01127334
Lead sponsor
University of Mississippi Medical Center
First posted
May 20, 2010
Start date
May 2010
Primary completion
May 2011
Completion
May 2011
Last update
Apr 4, 2012

Study contacts

Donny R. Stokes, M.D.
principal investigator · University of Mississippi Medical Center
John P. Payne, M.D.
study director · University of Mississippi Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion